We recently ran an industry survey to help us understand what the current industry standards are for when and why researchers are running various Absorption, Distribution, Metabolism, and Excretion (ADME) studies, including Drug Metabolism and Pharmacokinetics (DMPK) and Drug-Drug Interaction (DDI) research. With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies.
Take a look at the infographic to read about when most researchers are performing ADME/PK & DDI testing, see what the top 4 repercussions and risks are from postponing, and the top 3 benefits to running more ADME testing during preclinical research. View the Infographic and Survey Results
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback